4baseCare

4baseCare is focused on precision oncology, utilizing comprehensive genomic profiling (CGP) to enhance cancer treatment personalization. Their approach is based on identifying biomarkers within tumors, which allows for tailored treatment strategies for individual patients.

The company has conducted several clinical case studies demonstrating the effectiveness of CGP. One study highlights the role of CGP in overcoming cancer treatment challenges by personalizing therapy based on tumor biomarkers. Another case explores the significance of genetic testing in individuals with non-classical syndromes, such as those with a history of BRCA mutations.

4baseCare's research also includes the detection of rare oncogenic fusions, such as CD74-NRG1 in lung cancer patients, showcasing the value of CGP in identifying targetable alterations in patients without well-known driver mutations. Additionally, CGP is used to discover new treatment options for recurrent cancers, as demonstrated in a study on Leiomyosarcoma.

Further case studies reveal the importance of tumor DNA profiling for assessing EGFR mutation status in lung cancer, especially when liquid biopsy is ineffective. The benefits of CGP during disease progression in GIST are also highlighted, where it helps identify biomarkers for therapy resistance and provides alternative treatment options.

Moreover, 4baseCare has identified novel gene fusions, such as ESR1, which may explain resistance to endocrine therapy, offering potential therapeutic alternatives. These studies underscore the company's commitment to advancing cancer treatment through innovative genomic solutions.